Rate My Professor Henry Hui

Hui's research expertise lies in developing novel imaging flow cytometry protocols for high-throughput single-cell analysis, particularly for identifying chromosomal abnormalities in haematological malignancies such as chronic lymphocytic leukaemia, multiple myeloma, and paediatric acute lymphoblastic leukaemia. He co-invented 'Immuno-flowFISH,' an automated clinical methodology protected by Australian Provisional Patent 2017904274, which enables immunophenotyping combined with fluorescence in situ hybridization on imaging flow cytometers for precise cancer biomarker detection and minimal residual disease assessment. Key publications include 'Analysis of human chromosomes by imaging flow cytometry' (Cytometry Part B: Clinical Cytometry, 2021), 'Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma' (2024), 'Immuno‐flowFISH for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia' (Cytometry Part A, 2019), 'Measurement of monocyte‐platelet aggregates by imaging flow cytometry' (Cytometry Part A, 2015), and over 15 additional peer-reviewed articles, garnering 236 citations. His contributions have elevated standards in cancer cell biology and cytometry. Hui has received the ANSTO Eureka Prize for Innovative Use of Technology (Australian Museum, 2018), Cancer Council WA Early Career Researcher of the Year (2021), Raine Priming Grant ($224,649, 2022), and Raine Brightspark Research Collaboration Award ($29,864, 2021), underscoring his influence in translational medicine.